Badanie porównujące sam blinatumomab z blinatumomabem i niwolumabem u pacjentów z rozpoznaniem pierwszego nawrotu ostrej białaczki limfoblastycznej B-komórkowej (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
- Procedura: Bone Marrow Biopsy
- Biologiczny: Nivolumab
- Biologiczny: Blinatumomab
- Procedura: Bone Marrow Aspiration
- Procedura: Lumbar Puncture
- Lek: Mercaptopurine
- Lek: Pegaspargase
- Lek: Calaspargase Pegol
- Lek: Dexamethasone
- Lek: Asparaginase Erwinia chrysanthemi
- Lek: Cytarabine
- Procedura: Biospecimen Collection
- Lek: Hydrocortisone Sodium Succinate
- Lek: Methotrexate
- Promieniowanie: 3-Dimensional Conformal Radiation Therapy
- Lek: Vincristine Sulfate
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To compare event free survival post reinduction (EFS PR) between blinatumomab vs. blinatumomab/nivolumab in Group 4 patients aged ≥ 1 to <31 years old with first relapse of CD19+ B ALL.
II. To compare EFS PR (EFS post-reinduction) between consolidation with blinatumomab vs. blinatumomab/nivolumab in Group 3 patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of blinatumomab/nivolumab in patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
EXPLORATORY OBJECTIVES:
I. In Group 4 patients, compare EFS PR between blinatumomab monotherapy and blinatumomab/nivolumab arms as compared to similar patients treated on the predecessor trial AALL1331.
II. In Group 4 patients, compare toxicity as defined by grade 3 or greater adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab.
III. In Group 4 patients, compare MRD negative second remission (Rem-2) rate after the first cycle of immunotherapy between blinatumomab monotherapy and blinatumomab/nivolumab arms.
IV. In patients with Down syndrome (DS) with first relapse of B-ALL, describe the safety, tolerability and efficacy (as defined by MRD negative second remission, Rem-2) after up to two cycles of blinatumomab/nivolumab.
V. With each Group, perform subset analyses of EFS and overall survival (OS) based on features including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count at first relapse.
OUTLINE:
Patients >= 18 years old with marrow +/- extramedullary (EM) relapse of any duration after initial diagnosis, or patients < 18 years old with marrow +/- EM relapse < 24 months after initial diagnosis are assigned to Group 1. Patients < 18 years old with marrow +/- EM relapse >= 24 months from initial diagnosis, or all isolated extramedullary (IEM) relapses >= 1 to < 31 years old are assigned to Groups 2-3 re-induction. Patients with DS are assigned to Arm G. NOTE: Patients in Group 1 and DS patients with white blood cells (WBC) >= 30,000/uL, CNS 2/3 disease, or testicular disease must first receive 1 of 3 pre-immunotherapy treatments.
Starting with amendment 4C (9/19/2024), patients with DS are assigned to group 3 or 4. Patients < 18 years with bone marrow first relapse ≥ 36 months from initial diagnosis with MRD <0.1% after VXLD reinduction or with isolated CNS/testicular extramedullary relapse occurring ≥ 18 months from initial diagnosis with MRD <0.1% after VXLD reinduction are assigned to group 3. Patients who do not meet criteria for group 3 will be assigned to group 4. Patients with Down syndrome ≥ 1 to < 31 years of age with first bone marrow relapse of B ALL are assigned to arm G.
PRE-IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH WBC >= 30,000/uL (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G) : Patients receive methotrexate (MTX) intrathecally (IT) or cytarabine IT or intrathecal triple therapy (ITT) consisting of MTX, hydrocortisone sodium succinate, and cytarabine IT at the time of diagnostic lumbar puncture (LP) or on day 1 (if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients also receive dexamethasone intravenously (IV) or orally (PO) twice daily (BID) on days 1-5, vincristine sulfate via infusion or IV push over 1 minute on day 1. Patients with DS also receive leucovorin calcium PO or IV every 6 hours (q6h) for 2 doses on day 2 or at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 8 and no later than Day 15.
PRE-IMMUNOTHERAPY TREATMENT FOR CNS 2/3 DISEASE (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT or cytarabine IT twice weekly (Q2W) for 5-7 doses or Intrathecal Triple Therapy (ITT) IT Q2W for 3-4 doses until patient is CNS 1. Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 24.
PRE-IMMUNOTHERAPY TREATMENT FOR TESTICULAR DISEASE(CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT, cytarabine IT, or ITT IT on days 1 and 15 (day 1 may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses on days 2 and 16 or at 24 and 30 hours after each IT administration. Males with testicular disease at relapse undergo radiation once daily (QD) for a total of 12 fractions over 12 days. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 22.
GROUP 1 (CLOSED TO ACCRUAL 9/19/2024): Patients are randomized to Arm A or Arm B.
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM B: Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUPS 2-4 VXLD REINDUCTION: Patients receive vincristine sulfate via infusion or IV push over 1 minute on days 1, 8, 15, and 22, dexamethasone PO or IV on days 1-14, doxorubicin hydrochloride IV over 3-15 minutes on day 1, MTX IT on days 1, 8, and 29 (day 1 IT may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of this cycle) (days 8 and 29 for CNS 1 patients at relapse only), pegaspargase intramuscularly (IM) or IV over 1-2 hours on days 2 and 16 or calaspargase IV over 1-2 hours on day 2 (for patients ≤ 22 years), cytarabine IT on days 4 and 11 (CNS 2 patients at relapse only), then Q2W until 3 consecutive samples are clear of blasts, and ITT IT on days 8, 15, 22, and 29 (CNS 3 patients at relapse only). Patients with CNS 2 disease at relapse that does not resolve to CNS 1 by day 15 receive maintenance chemoradiation before initiation of maintenance. Treatment continues in the absence of disease progression or unacceptable toxicity.
GROUP 2 (CLOSED TO ACCRUAL 9/19/2024): The following patients are randomized to Arm C or Arm D: 1) >= 1 to < 31 years old, IEM relapse < 18 months from diagnosis, regardless of MRD after Re-Induction. 2) < 18 years old with marrow relapse >= 24 to < 36 months from diagnosis regardless of MRD after Re-Induction, 3) >= 1 to < 31 years old, IEM relapse >= 18 months, and MRD >= 0.1% after Re-Induction, 4) < 18 years old with marrow relapse >= 36 months, and MRD >= 0.1% after Re-Induction.
ARM C: Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and MTX IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal MTX is given < 7 days prior to the start of cycle 1 ). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM D: Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUP 3: Patients are randomized to Arm E or Arm F.
ARM E:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION: Patients receive dexamethasone PO or IV on days 1-5, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (Omit day 1 for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
ARM F:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and on days 1 of cycles 2 and 3, and MTX IT on days 1 and 15 (CNS 1/2 patients at relapse only)(day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle) or , ITT IT on days 1 and 15 (CNS 3 patients at relapse only) (day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on day 1 and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 (Omit for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
GROUP 4: Patients are randomized to arm H or arm I.
ARM H: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM I: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM G (DS PATIENTS): Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician.
Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
After completion of study treatment, patients are followed up every 3 months for 1 year.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australia, 2310
- Zawieszony
- John Hunter Children's Hospital
-
Randwick, New South Wales, Australia, 2031
- Zawieszony
- Sydney Children's Hospital
-
Westmead, New South Wales, Australia, 2145
- Zawieszony
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Zawieszony
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, 6009
- Zawieszony
- Perth Children's Hospital
-
-
-
-
-
Québec, Kanada, G1V 4G2
- Rekrutacyjny
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Główny śledczy:
- Bruno Michon
-
Kontakt:
- Site Public Contact
- Numer telefonu: 418-525-4444
- E-mail: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Zawieszony
- Alberta Children's Hospital
-
Edmonton, Alberta, Kanada, T6G 2B7
- Rekrutacyjny
- University of Alberta Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 780-407-8798
- E-mail: pedsoncologyresearch@ahs.ca
-
Główny śledczy:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- Zawieszony
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- Rekrutacyjny
- CancerCare Manitoba
-
Kontakt:
- Site Public Contact
- Numer telefonu: 866-561-1026
- E-mail: ctu_web@cancercare.mb.ca
-
Główny śledczy:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
- Rekrutacyjny
- Janeway Child Health Centre
-
Główny śledczy:
- Lisa A. Goodyear
-
Kontakt:
- Site Public Contact
- Numer telefonu: 709-777-8727
- E-mail: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- Rekrutacyjny
- IWK Health Centre
-
Kontakt:
- Site Public Contact
- Numer telefonu: 902-470-8520
- E-mail: Research@iwk.nshealth.ca
-
Główny śledczy:
- Chelsea Ash
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- Rekrutacyjny
- The Montreal Children's Hospital of the MUHC
-
Kontakt:
- Site Public Contact
- Numer telefonu: 514-412-4445
- E-mail: info@thechildren.com
-
Główny śledczy:
- Stephanie Mourad
-
Montreal, Quebec, Kanada, H3T 1C5
- Rekrutacyjny
- Centre Hospitalier Universitaire Sainte-Justine
-
Główny śledczy:
- Monia Marzouki
-
Kontakt:
- Site Public Contact
- Numer telefonu: 514-345-4931
- E-mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Rekrutacyjny
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Kontakt:
- Site Public Contact
- Numer telefonu: 819-820-6480
- E-mail: crcinformation.chus@ssss.gouv.qc.ca
-
Główny śledczy:
- Stephanie Vairy
-
-
-
-
-
San Juan, Portoryko, 00926
- Rekrutacyjny
- University Pediatric Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 787-474-0333
-
Główny śledczy:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- Rekrutacyjny
- Children's Hospital of Alabama
-
Kontakt:
- Site Public Contact
- Numer telefonu: 205-638-9285
- E-mail: oncologyresearch@peds.uab.edu
-
Główny śledczy:
- Matthew A. Kutny
-
Mobile, Alabama, Stany Zjednoczone, 36604
- Rekrutacyjny
- USA Health Strada Patient Care Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-388-8721
-
Główny śledczy:
- Hamayun Imran
-
-
Alaska
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Rekrutacyjny
- Providence Alaska Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 907-212-6871
- E-mail: AKPAMC.OncologyResearchSupport@providence.org
-
Główny śledczy:
- Brenda J. Wittman
-
-
Arizona
-
Kingman, Arizona, Stany Zjednoczone, 86401
- Zawieszony
- Kingman Regional Medical Center
-
Mesa, Arizona, Stany Zjednoczone, 85202
- Rekrutacyjny
- Banner Children's at Desert
-
Kontakt:
- Site Public Contact
- Numer telefonu: 480-412-3100
-
Główny śledczy:
- Joseph C. Torkildson
-
Phoenix, Arizona, Stany Zjednoczone, 85016
- Rekrutacyjny
- Phoenix Childrens Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 602-546-0920
-
Główny śledczy:
- Dana B. Salzberg
-
Tucson, Arizona, Stany Zjednoczone, 85719
- Rekrutacyjny
- Banner University Medical Center - Tucson
-
Kontakt:
- Site Public Contact
- E-mail: UACC-IIT@uacc.arizona.edu
-
Główny śledczy:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72202-3591
- Rekrutacyjny
- Arkansas Children's Hospital
-
Główny śledczy:
- Michael W. Bishop
-
Kontakt:
- Site Public Contact
- Numer telefonu: 501-364-7373
-
-
California
-
Anaheim, California, Stany Zjednoczone, 92806
- Zawieszony
- Kaiser Permanente-Anaheim
-
Arroyo Grande, California, Stany Zjednoczone, 93420
- Zawieszony
- PCR Oncology
-
Bellflower, California, Stany Zjednoczone, 90706
- Zawieszony
- Kaiser Permanente-Bellflower
-
Downey, California, Stany Zjednoczone, 90242
- Rekrutacyjny
- Kaiser Permanente Downey Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 626-564-3455
-
Główny śledczy:
- Robert M. Cooper
-
Duarte, California, Stany Zjednoczone, 91010
- Aktywny, nie rekrutujący
- City of Hope Comprehensive Cancer Center
-
Fontana, California, Stany Zjednoczone, 92335
- Rekrutacyjny
- Kaiser Permanente-Fontana
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Główny śledczy:
- Robert M. Cooper
-
Loma Linda, California, Stany Zjednoczone, 92354
- Rekrutacyjny
- Loma Linda University Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 909-558-4050
-
Główny śledczy:
- Albert Kheradpour
-
Long Beach, California, Stany Zjednoczone, 90806
- Rekrutacyjny
- Miller Children's and Women's Hospital Long Beach
-
Kontakt:
- Site Public Contact
- Numer telefonu: 562-933-5600
-
Główny śledczy:
- Jacqueline N. Casillas
-
Los Angeles, California, Stany Zjednoczone, 90027
- Rekrutacyjny
- Children's Hospital Los Angeles
-
Kontakt:
- Site Public Contact
- Numer telefonu: 323-361-4110
-
Główny śledczy:
- Jamie L. Stokke
-
Los Angeles, California, Stany Zjednoczone, 90048
- Rekrutacyjny
- Cedars-Sinai Medical Center
-
Główny śledczy:
- Nicole M. Baca
-
Kontakt:
- Site Public Contact
- Numer telefonu: 310-423-2133
- E-mail: Cancer.trial.info@cshs.org
-
Los Angeles, California, Stany Zjednoczone, 90095
- Rekrutacyjny
- Mattel Children's Hospital UCLA
-
Kontakt:
- Site Public Contact
- Numer telefonu: 310-825-6708
-
Główny śledczy:
- Satiro N. De Oliveira
-
Los Angeles, California, Stany Zjednoczone, 90027
- Zawieszony
- Kaiser Permanente Los Angeles Medical Center
-
Madera, California, Stany Zjednoczone, 93636
- Rekrutacyjny
- Valley Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 559-353-3000
- E-mail: Research@valleychildrens.org
-
Główny śledczy:
- Ruetima Titapiwatanakun
-
Oakland, California, Stany Zjednoczone, 94611
- Rekrutacyjny
- Kaiser Permanente-Oakland
-
Kontakt:
- Site Public Contact
- Numer telefonu: 877-642-4691
- E-mail: Kpoct@kp.org
-
Główny śledczy:
- Aarati V. Rao
-
Orange, California, Stany Zjednoczone, 92868
- Rekrutacyjny
- Children's Hospital of Orange County
-
Kontakt:
- Site Public Contact
- Numer telefonu: 714-509-8646
- E-mail: oncresearch@choc.org
-
Główny śledczy:
- Elyssa M. Rubin
-
Palo Alto, California, Stany Zjednoczone, 94304
- Rekrutacyjny
- Lucile Packard Children's Hospital Stanford University
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-694-0012
- E-mail: ccto-office@stanford.edu
-
Główny śledczy:
- Jay Michael S. Balagtas
-
Sacramento, California, Stany Zjednoczone, 95817
- Rekrutacyjny
- University of California Davis Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 916-734-3089
-
Główny śledczy:
- Marcio H. Malogolowkin
-
Sacramento, California, Stany Zjednoczone, 95816
- Rekrutacyjny
- Sutter Medical Center Sacramento
-
Kontakt:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Główny śledczy:
- Sandra Baril
-
San Diego, California, Stany Zjednoczone, 92120
- Rekrutacyjny
- Kaiser Permanente-San Diego Zion
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Główny śledczy:
- Robert M. Cooper
-
San Diego, California, Stany Zjednoczone, 92123
- Rekrutacyjny
- Rady Children's Hospital - San Diego
-
Kontakt:
- Site Public Contact
- Numer telefonu: 858-966-5934
-
Główny śledczy:
- William D. Roberts
-
San Francisco, California, Stany Zjednoczone, 94158
- Rekrutacyjny
- UCSF Medical Center-Mission Bay
-
Kontakt:
- Site Public Contact
- Numer telefonu: 877-827-3222
- E-mail: cancertrials@ucsf.edu
-
Główny śledczy:
- Karen R. Rabin
-
Torrance, California, Stany Zjednoczone, 90502
- Aktywny, nie rekrutujący
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- Children's Hospital Colorado
-
Główny śledczy:
- Kelly E. Faulk
-
Kontakt:
- Site Public Contact
- Numer telefonu: 303-764-5056
- E-mail: josh.b.gordon@nsmtp.kp.org
-
Denver, Colorado, Stany Zjednoczone, 80218
- Rekrutacyjny
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 303-832-2344
- E-mail: PSGResearchSharedMailbox@HCAHealthcare.com
-
Główny śledczy:
- Florence Choo
-
-
Connecticut
-
Hartford, Connecticut, Stany Zjednoczone, 06106
- Rekrutacyjny
- Connecticut Children's Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 860-545-9981
-
Główny śledczy:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, Stany Zjednoczone, 19803
- Rekrutacyjny
- Alfred I duPont Hospital for Children
-
Kontakt:
- Site Public Contact
- Numer telefonu: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Główny śledczy:
- Emi H. Caywood
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- Rekrutacyjny
- Children's National Medical Center
-
Główny śledczy:
- Jeffrey S. Dome
-
Kontakt:
- Site Public Contact
- Numer telefonu: 202-476-2800
- E-mail: OncCRC_OnCall@childrensnational.org
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20007
- Rekrutacyjny
- MedStar Georgetown University Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 202-444-2223
-
Główny śledczy:
- Caileigh Pudela
-
-
Florida
-
Fort Myers, Florida, Stany Zjednoczone, 33908
- Rekrutacyjny
- Golisano Children's Hospital of Southwest Florida
-
Kontakt:
- Site Public Contact
- Numer telefonu: 239-343-5333
- E-mail: molly.arnstrom@leehealth.org
-
Główny śledczy:
- Emad K. Salman
-
Gainesville, Florida, Stany Zjednoczone, 32610
- Rekrutacyjny
- UF Health Cancer Institute - Gainesville
-
Główny śledczy:
- Brian Stover
-
Kontakt:
- Site Public Contact
- Numer telefonu: 352-273-8010
-
Hollywood, Florida, Stany Zjednoczone, 33021
- Rekrutacyjny
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 954-265-1847
- E-mail: OHR@mhs.net
-
Główny śledczy:
- Iftikhar Hanif
-
Jacksonville, Florida, Stany Zjednoczone, 32207
- Rekrutacyjny
- Nemours Children's Clinic-Jacksonville
-
Kontakt:
- Site Public Contact
- Numer telefonu: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Główny śledczy:
- Emi H. Caywood
-
Orlando, Florida, Stany Zjednoczone, 32806
- Rekrutacyjny
- Arnold Palmer Hospital for Children
-
Główny śledczy:
- Jaime M. Libes-Bander
-
Kontakt:
- Site Public Contact
- Numer telefonu: 321-841-5357
- E-mail: Jennifer.spinelli@orlandohealth.com
-
Orlando, Florida, Stany Zjednoczone, 32827
- Rekrutacyjny
- Nemours Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Główny śledczy:
- Emi H. Caywood
-
Orlando, Florida, Stany Zjednoczone, 32803
- Rekrutacyjny
- AdventHealth Orlando
-
Kontakt:
- Site Public Contact
- Numer telefonu: 407-303-2090
- E-mail: FH.Cancer.Research@flhosp.org
-
Główny śledczy:
- Fouad M. Hajjar
-
Pensacola, Florida, Stany Zjednoczone, 32504
- Zawieszony
- Sacred Heart Hospital
-
Pensacola, Florida, Stany Zjednoczone, 32504
- Rekrutacyjny
- Nemours Children's Clinic - Pensacola
-
Kontakt:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Główny śledczy:
- Jeffrey H. Schwartz
-
St. Petersburg, Florida, Stany Zjednoczone, 33701
- Rekrutacyjny
- Johns Hopkins All Children's Hospital
-
Główny śledczy:
- Jennifer L. Mayer
-
Kontakt:
- Site Public Contact
- Numer telefonu: 727-767-4784
- E-mail: Ashley.Repp@jhmi.edu
-
Tampa, Florida, Stany Zjednoczone, 33606
- Rekrutacyjny
- Tampa General Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 813-844-7829
- E-mail: syapchanyk@tgh.org
-
Główny śledczy:
- Andrew J. Galligan
-
Tampa, Florida, Stany Zjednoczone, 33607
- Rekrutacyjny
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Kontakt:
- Site Public Contact
- Numer telefonu: 813-357-0849
- E-mail: jennifer.manns@baycare.org
-
Główny śledczy:
- Don E. Eslin
-
West Palm Beach, Florida, Stany Zjednoczone, 33407
- Rekrutacyjny
- Saint Mary's Medical Center
-
Główny śledczy:
- Matthew D. Ramirez
-
Kontakt:
- Site Public Contact
- Numer telefonu: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30329
- Rekrutacyjny
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Główny śledczy:
- Waitman K. Aumann
-
Kontakt:
- Site Public Contact
- Numer telefonu: 404-785-0232
- E-mail: Olivia.Floyd@choa.org
-
Savannah, Georgia, Stany Zjednoczone, 31404
- Rekrutacyjny
- Memorial Health University Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 912-350-7887
- E-mail: Lorraine.OHara@hcahealthcare.com
-
Główny śledczy:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Stany Zjednoczone, 96826
- Rekrutacyjny
- Kapiolani Medical Center for Women and Children
-
Kontakt:
- Site Public Contact
- Numer telefonu: 808-983-6090
-
Główny śledczy:
- Wade T. Kyono
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83712
- Rekrutacyjny
- Saint Luke's Cancer Institute - Boise
-
Główny śledczy:
- Martha M. Pacheco
-
Kontakt:
- Site Public Contact
- Numer telefonu: 208-381-2774
- E-mail: eslinget@slhs.org
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Rekrutacyjny
- Lurie Children's Hospital-Chicago
-
Kontakt:
- Site Public Contact
- Numer telefonu: 773-880-4562
-
Główny śledczy:
- Jenna Rossoff
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Rekrutacyjny
- University of Chicago Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Główny śledczy:
- Gabrielle Lapping-Carr
-
Chicago, Illinois, Stany Zjednoczone, 60612
- Rekrutacyjny
- University of Illinois
-
Kontakt:
- Site Public Contact
- Numer telefonu: 312-355-3046
-
Główny śledczy:
- Dipti S. Dighe
-
Maywood, Illinois, Stany Zjednoczone, 60153
- Rekrutacyjny
- Loyola University Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 708-226-4357
-
Główny śledczy:
- Eugene Suh
-
Peoria, Illinois, Stany Zjednoczone, 61637
- Rekrutacyjny
- OSF Children's Hospital of Illinois
-
Główny śledczy:
- Prerna Kumar
-
Kontakt:
- Site Public Contact
- Numer telefonu: 309-624-4945
- E-mail: ChildrensHospitalofIllinois@osfhealthcare.org
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Rekrutacyjny
- Riley Hospital for Children
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-248-1199
-
Główny śledczy:
- Sandeep Batra
-
Indianapolis, Indiana, Stany Zjednoczone, 46260
- Rekrutacyjny
- Ascension Saint Vincent Indianapolis Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 317-338-2194
- E-mail: research@stvincent.org
-
Główny śledczy:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- Rekrutacyjny
- Blank Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 515-241-8912
- E-mail: samantha.mallory@unitypoint.org
-
Główny śledczy:
- Samantha L. Mallory
-
Iowa City, Iowa, Stany Zjednoczone, 52242
- Rekrutacyjny
- University of Iowa/Holden Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-237-1225
-
Główny śledczy:
- Andrew P. Groves
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- Rekrutacyjny
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 859-257-3379
-
Główny śledczy:
- James T. Badgett
-
Louisville, Kentucky, Stany Zjednoczone, 40202
- Rekrutacyjny
- Norton Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 502-629-5500
- E-mail: CancerResource@nortonhealthcare.org
-
Główny śledczy:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Stany Zjednoczone, 70118
- Rekrutacyjny
- Children's Hospital New Orleans
-
Główny śledczy:
- Maria C. Velez-Yanguas
-
Kontakt:
- Site Public Contact
- Numer telefonu: 504-894-5377
-
New Orleans, Louisiana, Stany Zjednoczone, 70121
- Aktywny, nie rekrutujący
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Stany Zjednoczone, 04401
- Rekrutacyjny
- Eastern Maine Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 207-973-4274
-
Główny śledczy:
- Daniel L. Callaway
-
Scarborough, Maine, Stany Zjednoczone, 04074
- Rekrutacyjny
- Maine Children's Cancer Program
-
Główny śledczy:
- Eric C. Larsen
-
Kontakt:
- Site Public Contact
- Numer telefonu: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Rekrutacyjny
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Główny śledczy:
- Stacy L. Cooper
-
Kontakt:
- Site Public Contact
- Numer telefonu: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Baltimore, Maryland, Stany Zjednoczone, 21215
- Rekrutacyjny
- Sinai Hospital of Baltimore
-
Główny śledczy:
- Jason M. Fixler
-
Kontakt:
- Site Public Contact
- Numer telefonu: 410-601-9083
-
Bethesda, Maryland, Stany Zjednoczone, 20889-5600
- Zawieszony
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02111
- Aktywny, nie rekrutujący
- Tufts Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- Rekrutacyjny
- C S Mott Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-865-1125
-
Główny śledczy:
- Joshua W. Goldman
-
Battle Creek, Michigan, Stany Zjednoczone, 49017
- Zawieszony
- Bronson Battle Creek
-
Dearborn, Michigan, Stany Zjednoczone, 48124
- Zawieszony
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Stany Zjednoczone, 48201
- Zawieszony
- Children's Hospital of Michigan
-
East Lansing, Michigan, Stany Zjednoczone, 48823
- Aktywny, nie rekrutujący
- Michigan State University
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Zawieszony
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Rekrutacyjny
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Główny śledczy:
- Kathleen Y. Butler
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Zawieszony
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- Rekrutacyjny
- Bronson Methodist Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Główny śledczy:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- Zawieszony
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stany Zjednoczone, 49048
- Zawieszony
- Beacon Kalamazoo
-
Muskegon, Michigan, Stany Zjednoczone, 49444
- Zawieszony
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Stany Zjednoczone, 49120
- Zawieszony
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Stany Zjednoczone, 49444
- Zawieszony
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Stany Zjednoczone, 49677
- Zawieszony
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, Stany Zjednoczone, 48073
- Rekrutacyjny
- Corewell Health Children's
-
Kontakt:
- Site Public Contact
- Numer telefonu: 248-551-7695
-
Główny śledczy:
- Marie V. Nelson
-
Royal Oak, Michigan, Stany Zjednoczone, 48073
- Zawieszony
- Corewell Health William Beaumont University Hospital
-
Saint Joseph, Michigan, Stany Zjednoczone, 49085
- Zawieszony
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Stany Zjednoczone, 49085
- Zawieszony
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Stany Zjednoczone, 49684
- Zawieszony
- Munson Medical Center
-
Troy, Michigan, Stany Zjednoczone, 48085
- Zawieszony
- Corewell Health Beaumont Troy Hospital
-
Wyoming, Michigan, Stany Zjednoczone, 49519
- Zawieszony
- University of Michigan Health - West
-
-
Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55404
- Rekrutacyjny
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Główny śledczy:
- Michael K. Richards
-
Kontakt:
- Site Public Contact
- Numer telefonu: 612-813-5913
- E-mail: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Stany Zjednoczone, 55455
- Rekrutacyjny
- University of Minnesota/Masonic Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 612-624-2620
-
Główny śledczy:
- Peter M. Gordon
-
-
Mississippi
-
Jackson, Mississippi, Stany Zjednoczone, 39216
- Rekrutacyjny
- University of Mississippi Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 601-815-6700
-
Główny śledczy:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, Stany Zjednoczone, 64108
- Rekrutacyjny
- Children's Mercy Hospitals and Clinics
-
Główny śledczy:
- Keith J. August
-
Kontakt:
- Site Public Contact
- Numer telefonu: 816-302-6808
- E-mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Rekrutacyjny
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Główny śledczy:
- Kristin Zorn
-
St Louis, Missouri, Stany Zjednoczone, 63141
- Rekrutacyjny
- Mercy Hospital Saint Louis
-
Kontakt:
- Site Public Contact
- Numer telefonu: 314-251-7066
-
Główny śledczy:
- Robin D. Hanson
-
St Louis, Missouri, Stany Zjednoczone, 63104
- Rekrutacyjny
- Cardinal Glennon Children's Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 314-268-4000
-
Główny śledczy:
- William S. Ferguson
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68114
- Rekrutacyjny
- Children's Hospital and Medical Center of Omaha
-
Kontakt:
- Site Public Contact
- Numer telefonu: 402-955-3949
-
Główny śledczy:
- Jill C. Beck
-
Omaha, Nebraska, Stany Zjednoczone, 68198
- Rekrutacyjny
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Główny śledczy:
- Jill C. Beck
-
-
Nevada
-
Carson City, Nevada, Stany Zjednoczone, 89703
- Zawieszony
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Stany Zjednoczone, 89052
- Zawieszony
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Stany Zjednoczone, 89052
- Zawieszony
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Stany Zjednoczone, 89052
- Zawieszony
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Stany Zjednoczone, 89074
- Zawieszony
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Las Vegas, Nevada, Stany Zjednoczone, 89135
- Rekrutacyjny
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Kontakt:
- Site Public Contact
- Numer telefonu: 702-384-0013
- E-mail: research@sncrf.org
-
Główny śledczy:
- Joseph L. Lasky
-
Las Vegas, Nevada, Stany Zjednoczone, 89144
- Rekrutacyjny
- Summerlin Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 702-384-0013
- E-mail: research@sncrf.org
-
Główny śledczy:
- Joseph L. Lasky
-
Las Vegas, Nevada, Stany Zjednoczone, 89103
- Zawieszony
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89109
- Zawieszony
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Stany Zjednoczone, 89128
- Zawieszony
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Stany Zjednoczone, 89128
- Zawieszony
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Stany Zjednoczone, 89128
- Zawieszony
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Stany Zjednoczone, 89144
- Zawieszony
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Stany Zjednoczone, 89144
- Zawieszony
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Stany Zjednoczone, 89148-2405
- Zawieszony
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Stany Zjednoczone, 89148
- Zawieszony
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89169
- Zawieszony
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Stany Zjednoczone, 89102
- Zawieszony
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Stany Zjednoczone, 89183
- Zawieszony
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Stany Zjednoczone, 89048
- Zawieszony
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Stany Zjednoczone, 89502
- Rekrutacyjny
- Renown Regional Medical Center
-
Główny śledczy:
- Seema L. Rao
-
Kontakt:
- Site Public Contact
- Numer telefonu: 775-982-5050
- E-mail: Renown-CRD@renown.org
-
Reno, Nevada, Stany Zjednoczone, 89503
- Zawieszony
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Stany Zjednoczone, 89511
- Zawieszony
- Cancer Care Specialists - Reno
-
-
New Hampshire
-
Lebanon, New Hampshire, Stany Zjednoczone, 03756
- Rekrutacyjny
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Główny śledczy:
- Angela Ricci
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
- Rekrutacyjny
- Hackensack University Medical Center
-
Główny śledczy:
- Jing Chen
-
Kontakt:
- Site Public Contact
- Numer telefonu: 551-996-2897
-
Morristown, New Jersey, Stany Zjednoczone, 07960
- Rekrutacyjny
- Morristown Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 973-971-5900
-
Główny śledczy:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Stany Zjednoczone, 08903
- Rekrutacyjny
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Site Public Contact
- Numer telefonu: 732-235-7356
-
Główny śledczy:
- Richard A. Drachtman
-
New Brunswick, New Jersey, Stany Zjednoczone, 08901
- Rekrutacyjny
- Saint Peter's University Hospital
-
Główny śledczy:
- Nibal A. Zaghloul
-
Kontakt:
- Site Public Contact
- Numer telefonu: 732-745-8600
- E-mail: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Stany Zjednoczone, 08903
- Rekrutacyjny
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 732-235-8675
-
Główny śledczy:
- Richard A. Drachtman
-
Newark, New Jersey, Stany Zjednoczone, 07112
- Rekrutacyjny
- Newark Beth Israel Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 973-926-7230
- E-mail: Christine.Kosmides@rwjbh.org
-
Główny śledczy:
- Teena Bhatla
-
Paterson, New Jersey, Stany Zjednoczone, 07503
- Rekrutacyjny
- Saint Joseph's Regional Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 973-754-2207
- E-mail: HallL@sjhmc.org
-
Główny śledczy:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Stany Zjednoczone, 87106
- Rekrutacyjny
- Presbyterian Hospital
-
Główny śledczy:
- Beeling Armijo
-
Kontakt:
- Site Public Contact
- Numer telefonu: 505-559-6113
- E-mail: wburman@phs.org
-
-
New York
-
Albany, New York, Stany Zjednoczone, 12208
- Rekrutacyjny
- Albany Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 518-262-5513
-
Główny śledczy:
- Lauren R. Weintraub
-
Brooklyn, New York, Stany Zjednoczone, 11219
- Rekrutacyjny
- Maimonides Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 718-765-2500
-
Główny śledczy:
- Mahmut Y. Celiker
-
Mineola, New York, Stany Zjednoczone, 11501
- Rekrutacyjny
- NYU Langone Hospital - Long Island
-
Kontakt:
- Site Public Contact
- Numer telefonu: 212-263-4432
- E-mail: cancertrials@nyulangone.org
-
Główny śledczy:
- Chana L. Glasser
-
New Hyde Park, New York, Stany Zjednoczone, 11040
- Rekrutacyjny
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Kontakt:
- Site Public Contact
- Numer telefonu: 718-470-3460
-
Główny śledczy:
- Julie I. Krystal
-
New York, New York, Stany Zjednoczone, 10032
- Rekrutacyjny
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Główny śledczy:
- Nobuko Hijiya
-
Kontakt:
- Site Public Contact
- Numer telefonu: 212-342-5162
- E-mail: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Stany Zjednoczone, 10065
- Rekrutacyjny
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 212-639-7592
-
Główny śledczy:
- Kavitha Ramaswamy
-
New York, New York, Stany Zjednoczone, 10016
- Rekrutacyjny
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Główny śledczy:
- Elizabeth A. Raetz
-
Kontakt:
- Site Public Contact
- E-mail: CancerTrials@nyulangone.org
-
New York, New York, Stany Zjednoczone, 10065
- Rekrutacyjny
- NYP/Weill Cornell Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 212-746-1848
-
Główny śledczy:
- Jaclyn Rosenzweig
-
Rochester, New York, Stany Zjednoczone, 14642
- Aktywny, nie rekrutujący
- University of Rochester
-
Stony Brook, New York, Stany Zjednoczone, 11794
- Rekrutacyjny
- Stony Brook University Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-862-2215
-
Główny śledczy:
- Laura E. Hogan
-
Syracuse, New York, Stany Zjednoczone, 13210
- Rekrutacyjny
- State University of New York Upstate Medical University
-
Kontakt:
- Site Public Contact
- Numer telefonu: 315-464-5476
-
Główny śledczy:
- Melanie A. Comito
-
The Bronx, New York, Stany Zjednoczone, 10467
- Rekrutacyjny
- Montefiore Medical Center - Moses Campus
-
Kontakt:
- Site Public Contact
- Numer telefonu: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Główny śledczy:
- Alice Lee
-
-
North Carolina
-
Asheville, North Carolina, Stany Zjednoczone, 28801
- Rekrutacyjny
- Mission Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 828-213-7055
- E-mail: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Główny śledczy:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
- Rekrutacyjny
- UNC Lineberger Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 877-668-0683
- E-mail: cancerclinicaltrials@med.unc.edu
-
Główny śledczy:
- Thomas B. Alexander
-
Charlotte, North Carolina, Stany Zjednoczone, 28203
- Rekrutacyjny
- Carolinas Medical Center/Levine Cancer Institute
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-804-9376
-
Główny śledczy:
- Joel A. Kaplan
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Rekrutacyjny
- Duke University Medical Center
-
Główny śledczy:
- Jessica M. Sun
-
Kontakt:
- Site Public Contact
- Numer telefonu: 888-275-3853
-
Greenville, North Carolina, Stany Zjednoczone, 27834
- Rekrutacyjny
- East Carolina University
-
Kontakt:
- Site Public Contact
- Numer telefonu: 252-744-1015
- E-mail: eubankss@ecu.edu
-
Główny śledczy:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Rekrutacyjny
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Numer telefonu: 336-713-6771
-
Główny śledczy:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Stany Zjednoczone, 58122
- Rekrutacyjny
- Sanford Broadway Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Główny śledczy:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Stany Zjednoczone, 44308
- Rekrutacyjny
- Children's Hospital Medical Center of Akron
-
Kontakt:
- Site Public Contact
- Numer telefonu: 330-543-3193
-
Główny śledczy:
- Lauren R. Draper
-
Cincinnati, Ohio, Stany Zjednoczone, 45229
- Rekrutacyjny
- Cincinnati Children's Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 513-636-2799
- E-mail: cancer@cchmc.org
-
Główny śledczy:
- Erin H. Breese
-
Cleveland, Ohio, Stany Zjednoczone, 44106
- Rekrutacyjny
- Rainbow Babies and Childrens Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 216-844-5437
-
Główny śledczy:
- Duncan S. Stearns
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Zawieszony
- Cleveland Clinic Foundation
-
Columbus, Ohio, Stany Zjednoczone, 43205
- Rekrutacyjny
- Nationwide Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Główny śledczy:
- Mark A. Ranalli
-
Dayton, Ohio, Stany Zjednoczone, 45404
- Rekrutacyjny
- Dayton Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-228-4055
-
Główny śledczy:
- Jordan M. Wright
-
Sylvania, Ohio, Stany Zjednoczone, 43560
- Zawieszony
- ProMedica Flower Hospital
-
Toledo, Ohio, Stany Zjednoczone, 43606
- Rekrutacyjny
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 419-824-1842
- E-mail: PCIOncResearch@promedica.org
-
Główny śledczy:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- Rekrutacyjny
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Główny śledczy:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Stany Zjednoczone, 74136
- Rekrutacyjny
- Saint Francis Children's Hospital
-
Główny śledczy:
- Jill A. Salo
-
Kontakt:
- Site Public Contact
- Numer telefonu: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97227
- Rekrutacyjny
- Legacy Emanuel Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 503-413-2560
-
Główny śledczy:
- Jason M. Glover
-
Portland, Oregon, Stany Zjednoczone, 97239
- Rekrutacyjny
- Oregon Health and Science University
-
Kontakt:
- Site Public Contact
- Numer telefonu: 503-494-1080
- E-mail: trials@ohsu.edu
-
Główny śledczy:
- Bill H. Chang
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stany Zjednoczone, 18103
- Rekrutacyjny
- Lehigh Valley Hospital-Cedar Crest
-
Kontakt:
- Site Public Contact
- Numer telefonu: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Główny śledczy:
- Jacob A. Troutman
-
Danville, Pennsylvania, Stany Zjednoczone, 17822
- Rekrutacyjny
- Geisinger Medical Center
-
Główny śledczy:
- Jagadeesh Ramdas
-
Kontakt:
- Site Public Contact
- Numer telefonu: 570-271-5251
- E-mail: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, Stany Zjednoczone, 17033
- Rekrutacyjny
- Penn State Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 717-531-6012
-
Główny śledczy:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- Rekrutacyjny
- Children's Hospital of Philadelphia
-
Główny śledczy:
- Shannon L. Maude
-
Kontakt:
- Site Public Contact
- Numer telefonu: 267-425-5544
- E-mail: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19134
- Rekrutacyjny
- Saint Christopher's Hospital for Children
-
Kontakt:
- Site Public Contact
- Numer telefonu: 215-427-8991
-
Główny śledczy:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15224
- Rekrutacyjny
- Children's Hospital of Pittsburgh of UPMC
-
Kontakt:
- Site Public Contact
- Numer telefonu: 412-692-8570
- E-mail: jean.tersak@chp.edu
-
Główny śledczy:
- Jenny Ruiz
-
-
Rhode Island
-
Providence, Rhode Island, Stany Zjednoczone, 02903
- Rekrutacyjny
- Rhode Island Hospital
-
Główny śledczy:
- Bradley DeNardo
-
Kontakt:
- Site Public Contact
- Numer telefonu: 401-444-1488
-
-
South Carolina
-
Columbia, South Carolina, Stany Zjednoczone, 29203
- Rekrutacyjny
- Prisma Health Richland Hospital
-
Główny śledczy:
- Stuart L. Cramer
-
Kontakt:
- Site Public Contact
- Numer telefonu: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Rekrutacyjny
- BI-LO Charities Children's Cancer Center
-
Główny śledczy:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Numer telefonu: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stany Zjednoczone, 29615
- Rekrutacyjny
- Prisma Health Cancer Institute - Eastside
-
Główny śledczy:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Numer telefonu: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57117-5134
- Rekrutacyjny
- Sanford USD Medical Center - Sioux Falls
-
Kontakt:
- Site Public Contact
- Numer telefonu: 605-312-3320
- E-mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Główny śledczy:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Stany Zjednoczone, 37916
- Rekrutacyjny
- East Tennessee Childrens Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 865-541-8266
-
Główny śledczy:
- Susan E. Spiller
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Rekrutacyjny
- Vanderbilt University/Ingram Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-811-8480
-
Główny śledczy:
- Brianna N. Smith
-
Nashville, Tennessee, Stany Zjednoczone, 37203
- Rekrutacyjny
- The Children's Hospital at TriStar Centennial
-
Kontakt:
- Site Public Contact
- Numer telefonu: 615-342-1919
-
Główny śledczy:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78723
- Rekrutacyjny
- Dell Children's Medical Center of Central Texas
-
Kontakt:
- Site Public Contact
- Numer telefonu: 512-628-1902
- E-mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Główny śledczy:
- Shannon M. Cohn
-
Corpus Christi, Texas, Stany Zjednoczone, 78411
- Rekrutacyjny
- Driscoll Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 361-694-5311
- E-mail: Crystal.DeLosSantos@dchstx.org
-
Główny śledczy:
- Nkechi I. Mba
-
Dallas, Texas, Stany Zjednoczone, 75390
- Rekrutacyjny
- UT Southwestern/Simmons Cancer Center-Dallas
-
Kontakt:
- Site Public Contact
- Numer telefonu: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Główny śledczy:
- Tamra L. Slone
-
Dallas, Texas, Stany Zjednoczone, 75230
- Rekrutacyjny
- Medical City Dallas Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 972-566-5588
-
Główny śledczy:
- Maurizio L. Ghisoli
-
El Paso, Texas, Stany Zjednoczone, 79905
- Rekrutacyjny
- El Paso Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 915-298-5444
- E-mail: ranjan.bista@ttuhsc.edu
-
Główny śledczy:
- Benjamin Carcamo
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- Rekrutacyjny
- Cook Children's Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 682-885-2103
- E-mail: CookChildrensResearch@cookchildrens.org
-
Główny śledczy:
- Kenneth M. Heym
-
Houston, Texas, Stany Zjednoczone, 77030
- Rekrutacyjny
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Główny śledczy:
- Anil George
-
Kontakt:
- Site Public Contact
- Numer telefonu: 713-798-1354
- E-mail: burton@bcm.edu
-
Houston, Texas, Stany Zjednoczone, 77030
- Rekrutacyjny
- UT MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 866-632-6789
- E-mail: askmdanderson@mdanderson.org
-
Główny śledczy:
- Najat C. Daw
-
Lubbock, Texas, Stany Zjednoczone, 79410
- Rekrutacyjny
- Covenant Children's Hospital
-
Główny śledczy:
- Kishor M. Bhende
-
Kontakt:
- Site Public Contact
- Numer telefonu: 806-725-8657
- E-mail: mbisbee@providence.org
-
Lubbock, Texas, Stany Zjednoczone, 79415
- Rekrutacyjny
- UMC Cancer Center / UMC Health System
-
Kontakt:
- Site Public Contact
- Numer telefonu: 806-775-8590
-
Główny śledczy:
- Erin K. Barr
-
San Antonio, Texas, Stany Zjednoczone, 78207
- Rekrutacyjny
- Children's Hospital of San Antonio
-
Kontakt:
- Site Public Contact
- Numer telefonu: 210-704-2894
- E-mail: bridget.medina@christushealth.org
-
Główny śledczy:
- Julie Voeller
-
San Antonio, Texas, Stany Zjednoczone, 78229
- Rekrutacyjny
- University of Texas Health Science Center at San Antonio
-
Kontakt:
- Site Public Contact
- Numer telefonu: 210-450-3800
- E-mail: phoresearchoffice@uthscsa.edu
-
Główny śledczy:
- Anne-Marie R. Langevin
-
San Antonio, Texas, Stany Zjednoczone, 78229
- Rekrutacyjny
- Methodist Children's Hospital of South Texas
-
Kontakt:
- Site Public Contact
- Numer telefonu: 210-575-6240
- E-mail: Vinod.GidvaniDiaz@hcahealthcare.com
-
Główny śledczy:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84113
- Rekrutacyjny
- Primary Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 801-585-5270
-
Główny śledczy:
- Luke D. Maese
-
-
Vermont
-
Burlington, Vermont, Stany Zjednoczone, 05405
- Rekrutacyjny
- University of Vermont and State Agricultural College
-
Kontakt:
- Site Public Contact
- Numer telefonu: 802-656-8990
- E-mail: rpo@uvm.edu
-
Główny śledczy:
- Jessica L. Heath
-
-
Virginia
-
Falls Church, Virginia, Stany Zjednoczone, 22042
- Rekrutacyjny
- Inova Fairfax Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 703-208-6650
- E-mail: Stephanie.VanBebber@inova.org
-
Główny śledczy:
- Robin Y. Dulman
-
Norfolk, Virginia, Stany Zjednoczone, 23507
- Rekrutacyjny
- Children's Hospital of The King's Daughters
-
Kontakt:
- Site Public Contact
- Numer telefonu: 757-668-7243
- E-mail: CCBDCresearch@chkd.org
-
Główny śledczy:
- Melissa S. Mark
-
Richmond, Virginia, Stany Zjednoczone, 23298
- Rekrutacyjny
- VCU Massey Comprehensive Cancer Center
-
Główny śledczy:
- Jordyn R. Griffin
-
Kontakt:
- Site Public Contact
- Numer telefonu: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, Stany Zjednoczone, 98004
- Zawieszony
- Overlake Medical Center
-
Renton, Washington, Stany Zjednoczone, 98055
- Zawieszony
- Valley Medical Center
-
Seattle, Washington, Stany Zjednoczone, 98105
- Rekrutacyjny
- Seattle Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 866-987-2000
-
Główny śledczy:
- Sarah E. Leary
-
Spokane, Washington, Stany Zjednoczone, 99204
- Rekrutacyjny
- Providence Sacred Heart Medical Center and Children's Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-228-6618
- E-mail: HopeBeginsHere@providence.org
-
Główny śledczy:
- Judy L. Felgenhauer
-
Tacoma, Washington, Stany Zjednoczone, 98405
- Rekrutacyjny
- Mary Bridge Children's Hospital and Health Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 253-403-1461
- E-mail: research@multicare.org
-
Główny śledczy:
- Robert G. Irwin
-
Tacoma, Washington, Stany Zjednoczone, 98431
- Rekrutacyjny
- Madigan Army Medical Center
-
Główny śledczy:
- Melissa A. Forouhar
-
Kontakt:
- Site Public Contact
- Numer telefonu: 253-968-6144
- E-mail: melissa.a.forouhar.mil@health.mil
-
Yakima, Washington, Stany Zjednoczone, 98902
- Zawieszony
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Bridgeport, West Virginia, Stany Zjednoczone, 26330
- Zawieszony
- United Hospital Center
-
Charleston, West Virginia, Stany Zjednoczone, 25304
- Rekrutacyjny
- Vandalia Health/CAMC Institute for Academic Medicine
-
Główny śledczy:
- Mohamad H. Badawi
-
Kontakt:
- Site Public Contact
- Numer telefonu: 304-388-9944
- E-mail: CAMCClinicalTrials@vandaliahealth.org
-
Martinsburg, West Virginia, Stany Zjednoczone, 25401
- Zawieszony
- WVUH-Berkely Medical Center
-
Morgantown, West Virginia, Stany Zjednoczone, 26506
- Rekrutacyjny
- West Virginia University Healthcare
-
Kontakt:
- Site Public Contact
- Numer telefonu: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Główny śledczy:
- Ashley E. Meyer
-
Parkersburg, West Virginia, Stany Zjednoczone, 26101
- Zawieszony
- Camden Clark Medical Center
-
-
Wisconsin
-
Green Bay, Wisconsin, Stany Zjednoczone, 54301
- Rekrutacyjny
- Saint Vincent Hospital Cancer Center Green Bay
-
Główny śledczy:
- Catherine A. Long
-
Kontakt:
- Site Public Contact
- Numer telefonu: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- Rekrutacyjny
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Główny śledczy:
- Cathy A. Lee-Miller
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53226
- Rekrutacyjny
- Children's Hospital of Wisconsin
-
Kontakt:
- Site Public Contact
- Numer telefonu: 414-955-4727
- E-mail: MACCCTO@mcw.edu
-
Główny śledczy:
- Michael J. Burke
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patients must be >= 1 and < 31 years at time of enrollment
-
Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories:
- Isolated bone marrow relapse
- Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
- Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes
-
Patients with Down syndrome (DS) are eligible in the following categories:
- Isolated bone marrow relapse
- Combined bone marrow with CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
- Of note, for patients with developmental delay (e.g., Down syndrome) regardless of age, Lansky scale may be substituted for Karnofsky scale. However, the requirement for ECOG 0-2 remains, regardless of known history of developmental delay
-
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
-
Patients with prior blinatumomab or CD19+ chimeric antigen receptor therapy in the upfront setting will be eligible, provided relapsed lymphoblasts retain CD19 expression
-
Patients must not have had a prior hematopoietic stem cell transplant
-
A single intrathecal chemotherapy at the time of relapse will be allowed. If < 7 days have elapsed between this intrathecal therapy (IT) and the start of protocol therapy, then the day 1 intrathecal chemotherapy (i.e. methotrexate, cytarabine, or triple intrathecal) may be omitted
-
In the 28 days prior to enrollment, up to five days of post-relapse, pre-enrollment therapy (steroids and/or hydroxyurea only) is permissible
- Patients with Down syndrome who received pre-enrollment therapy and have a white blood count (WBC) >= 30,000/ul at the time of enrollment still must receive protocol specified cytoreductive therapy with vincristine and dexamethasone, and no "washout" is required
- Patients with Down syndrome who received pre-enrollment therapy and have a WBC < 30,000/ul at the time of enrollment must be given a 24 hour "washout" before starting immunotherapy
-
Note: There is no waiting period or "washout" for patients who relapse while receiving upfront therapy
-
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/sex as follows (within 7 calendar days prior to enrollment):
-
Age: Maximum serum creatinine (mg/dL)
-
1 to < 2 years: 0.6 (male), 0.6 (female)
-
2 to < 6 years: 0.8 (male), 0.8 (female)
-
6 to < 10 years: 1 (male), 1 (female)
-
10 to < 13 years: 1.2 (male), 1.2 (female)
-
13 to < 16 years: 1.5 (male), 1.4 (female)
-
>= 16 years: 1.7 (male), 1.4 (female)
- The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the Center for Disease Control (CDC)
-
-
-
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by echocardiogram, cardiac magnetic resonance imaging (MRI) or radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Patients with B-lymphoblastic lymphoma (B-LLy)
-
Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia
-
Patients with Philadelphia chromosome positive (Ph+) B-ALL or ABL class Ph-like B-ALL (i.e. rearrangements involving ABL1, ABL2, CSF1R or PDGFRB and predicted to be sensitive to imatinib or dasatinib)
-
Patients with mixed phenotype acute leukemia (MPAL)
-
Patients with known Charcot-Marie-Tooth disease
-
Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype
-
Patients with active, uncontrolled infection defined as:
- Positive bacterial blood culture within 48 hours of study enrollment
- Receiving IV or PO antibiotics for an infection with continued signs or symptoms. Note: Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection if cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with clostridium (C.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline.
- Fever above 38.2 degrees Celsius (C) within 48 hours of study enrollment with clinical signs of infection. Fever without clinical signs of infection that is attributed to tumor burden is allowed if blood cultures are negative for > 48 hours
- A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection
- Active viral or protozoal infection requiring IV treatment
-
Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome are not eligible.
-
Patients with uncontrolled HIV, hepatitis B, or hepatitis C infection. Of note, patients with known human immunodeficiency virus (HIV) infection on effective anti-retroviral therapy with undetectable viral load for at least the last 6 months prior to enrollment are eligible. Similarly, hepatitis B and hepatitis C positive patients who have been treated and have no viral detectable burden are also eligible
-
Patients with significant central nervous system pathology that would preclude treatment with blinatumomab, including history of severe neurologic disorder or autoimmune disease with CNS involvement
- Note: Patients with a history of seizures that are well controlled on stable doses of anti-epileptic drugs are eligible Patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits are not eligible. Patients with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved
-
Patients with an active known/suspected autoimmune disease are not eligible. However, patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
-
Patients with DS patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are not eligible
- Note: Group 3 and 4 patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are eligible if this is NOT the only site of relapsed disease
-
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days prior to enrollment. Patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of this study. Men with female partners of childbearing potential should use effective contraception during the duration of their treatment. The effect of blinatumomab on fertility has not been evaluated. Blinatumomab is not recommended for pregnant women or women of childbearing potential (WOCBP) not using contraception. Females of reproductive potential must use effective contraception during treatment and for at least 48 hours after the last dose of blinatumomab. Studies in animal models have shown that nivolumab can adversely impair pregnancy. Thus, nivolumab is expected to cause fetal harm during pregnancy. WOCBP receiving nivolumab must continue contraception for a period of at least 5 months after the last dose of nivolumab. It is unknown whether nivolumab is present in breast milk, thus breastfeeding should be discontinued while a patient is receiving nivolumab
-
Lactating females are not eligible unless they agree to not breastfeed their infants. It is unknown whether blinatumomab or its metabolites are excreted in human breast milk. Women are not permitted to breastfeed while receiving blinatumomab and for the last 48 hours after the last blinatumomab dose. Due to the potential for serious adverse reactions in the breastfed infant, women are not permitted to breastfeed during treatment and for 5 months after the last nivolumab dose
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients
Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo bone marrow aspiration Undergo lumbar puncture
Inne nazwy:
Given PO or IV
Inne nazwy:
Given IT
Inne nazwy:
Undergo blood, urine and cerebrospinal fluid collection
Inne nazwy:
Given IT
Inne nazwy:
Given IT, PO, and IV
Inne nazwy:
|
|
Eksperymentalny: Group 1, Arm A (dexamethasone, blinatumomab, MTX)
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Inne nazwy:
Given IV
Inne nazwy:
Undergo bone marrow aspiration Undergo lumbar puncture
Inne nazwy:
Given PO or IV
Inne nazwy:
Given IT
Inne nazwy:
Undergo blood, urine and cerebrospinal fluid collection
Inne nazwy:
Given IT
Inne nazwy:
Given IT, PO, and IV
Inne nazwy:
|
|
Eksperymentalny: Group 1, Arm B (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo bone marrow aspiration Undergo lumbar puncture
Inne nazwy:
Given PO or IV
Inne nazwy:
Given IT
Inne nazwy:
Undergo blood, urine and cerebrospinal fluid collection
Inne nazwy:
Given IT
Inne nazwy:
Given IT, PO, and IV
Inne nazwy:
|
|
Eksperymentalny: Group 2, Arm C (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Inne nazwy:
Given IV
Inne nazwy:
Undergo bone marrow aspiration Undergo lumbar puncture
Inne nazwy:
Given PO or IV
Inne nazwy:
Undergo blood, urine and cerebrospinal fluid collection
Inne nazwy:
Given IT, PO, and IV
Inne nazwy:
|
|
Eksperymentalny: Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo bone marrow aspiration Undergo lumbar puncture
Inne nazwy:
Given PO or IV
Inne nazwy:
Undergo blood, urine and cerebrospinal fluid collection
Inne nazwy:
Given IT, PO, and IV
Inne nazwy:
|
|
Eksperymentalny: Group 3, Arm E (dexamethasone, blinatumomab, MTX)
See Outline section |
Undergo bone marrow biopsy
Inne nazwy:
Given IV
Inne nazwy:
Undergo bone marrow aspiration Undergo lumbar puncture
Inne nazwy:
Given PO
Inne nazwy:
Given IM or IV
Inne nazwy:
Given IV
Inne nazwy:
Given PO or IV
Inne nazwy:
Given IM
Inne nazwy:
Given IT
Inne nazwy:
Undergo blood, urine and cerebrospinal fluid collection
Inne nazwy:
Given IT
Inne nazwy:
Given IT, PO, and IV
Inne nazwy:
Undergo 3D-CRT
Inne nazwy:
Given IV push or via infusion
Inne nazwy:
|
|
Eksperymentalny: Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)
See Outline section |
Undergo bone marrow biopsy
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo bone marrow aspiration Undergo lumbar puncture
Inne nazwy:
Given PO
Inne nazwy:
Given IM or IV
Inne nazwy:
Given IV
Inne nazwy:
Given PO or IV
Inne nazwy:
Given IM
Inne nazwy:
Given IT
Inne nazwy:
Undergo blood, urine and cerebrospinal fluid collection
Inne nazwy:
Given IT
Inne nazwy:
Given IT, PO, and IV
Inne nazwy:
Undergo 3D-CRT
Inne nazwy:
Given IV push or via infusion
Inne nazwy:
|
|
Eksperymentalny: Group 4 Arm I (Dexamethasone, blinatumomab, nivolumab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Undergo bone marrow aspiration Undergo lumbar puncture
Inne nazwy:
Given IV
Inne nazwy:
Given PO or IV
Inne nazwy:
Given IT
Inne nazwy:
Undergo blood, urine and cerebrospinal fluid collection
Inne nazwy:
Given IT
Inne nazwy:
Given IT, PO, and IV
Inne nazwy:
|
|
Eksperymentalny: Group 4, Arm H (dexamethasone blinatumomab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Inne nazwy:
Given IV
Inne nazwy:
Undergo bone marrow aspiration Undergo lumbar puncture
Inne nazwy:
Given PO or IV
Inne nazwy:
Given IT
Inne nazwy:
Undergo blood, urine and cerebrospinal fluid collection
Inne nazwy:
Given IT
Inne nazwy:
Given IT, PO, and IV
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Minimal residual disease (MRD) negative second remission (Rem-2) rate with blinatumomab vs with blinatumomab + nivolumab (Group 1)
Ramy czasowe: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 be defined as Rem-2 (i.e., achievement of MRD < 1% blasts by flow cytometry and resolution of extramedullary disease (for CNS disease, requires CNS 1) ) and bone marrow with MRD < 0.01% by flow cytometry. MRD negative Rem-2 rate between Arm A vs Arm B will be compared using a one-sided Z test of proportions with Type I error of 0.10. Interim analysis will be conducted to monitor for futility. The futility boundaries are based on testing the alternative hypothesis at the 0.067 level. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Event-free survival post-reinduction (EFS PR) (Group 3)
Ramy czasowe: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm E versus Arm F will be based on a one-sided two-sample logrank test with Type I error of 0.15, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
|
EFS PR (Group 4)
Ramy czasowe: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm H versus Arm I will be based on a one-sided two-sample logrank test with Type I error of 0.10, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Dose-limiting toxicity
Ramy czasowe: Up to 1 cycle of therapy (each cycle = 36 days)
|
Will be assessed using the Common Terminology Criteria for Adverse Events version 5.0. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
Ramy czasowe: From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
Comparison of EFS post-reinduction between Arm C versus Arm D will be based on a one-sided two-sample logrank test with type I error of 0.15, to be conducted 2 years after completion of enrollment of Group 2. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. |
From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Event-free survival (Group 1)
Ramy czasowe: From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
EFS will be compared between Arm A and Arm B, and to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. |
From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
|
Event free survival (Group 4)
Ramy czasowe: From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
EFS of Arm H and Arm I will be compared to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
|
Incidence of adverse events in Arm A or Arm B
Ramy czasowe: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events in Arm H or Arm I
Ramy czasowe: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Group 2)
Ramy czasowe: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 rate will be estimated and be compared between Arm C and Arm D using two-sample test of proportions. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Dose-limiting toxicity (Down syndrome patients)
Ramy czasowe: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events (Down syndrome patients)
Ramy czasowe: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Down syndrome patients)
Ramy czasowe: Up to 2 cycles of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of EFS
Ramy czasowe: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of OS
Ramy czasowe: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
Ramy czasowe: At 2 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm H and I. |
At 2 years from date of randomization
|
|
EFS PR (Group 3)
Ramy czasowe: At 3 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm E and F. |
At 3 years from date of randomization
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Stacy L Cooper, Children's Oncology Group
Publikacje i pomocne linki
Publikacje ogólne
- Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704.
- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Objawy neurologiczne
- Choroby Układu Nerwowego
- Nowotwory
- Choroby genetyczne, wrodzone
- Choroby układu odpornościowego
- Infekcje
- Choroby wirusowe
- Nowotwory według typu histologicznego
- Manifestacje neurobehawioralne
- Infekcje wirusami DNA
- Choroby limfatyczne
- Zaburzenia limfoproliferacyjne
- Zaburzenia immunoproliferacyjne
- Chłoniak nieziarniczy
- Wady wrodzone
- Chłoniak z komórek B
- Chłoniak
- Nieprawidłowości, mnogość
- Upośledzenie intelektualne
- Zakażenia wirusem Epsteina-Barra
- Infekcje Herpesviridae
- Zakażenia wirusem nowotworowym
- Zaburzenia chromosomowe
- Wrodzone, dziedziczne i noworodkowe choroby i nieprawidłowości
- Choroby hemowe i limfatyczne
- Chłoniak Burkitta
- Zespół Downa
- Hormony
- Hormony, substytuty hormonów i antagoniści hormonów
- Aminokwasy, peptydy i białka
- Białka
- Związki siarki
- Organiczne chemikalia
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Związki heterocykliczne, 2-ring
- Związki heterocykliczne, sterowanie stopieniem
- Techniki śledcze
- Lecznictwo
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Nakłucia
- Procedury chirurgiczne, operacyjny
- Techniki cytologiczne
- Kwasy nukleinowe, nukleotydy i nukleozydy
- Cytodiagnoza
- Węglowodory
- Węglowodory, cykliczne
- Alkaloidy
- Węglowodory, aromatyczne
- Związki policykliczne
- Hydrolazy
- Enzymy
- Enzymy i koenzymy
- Indole
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Puryny
- Cytydyna
- Nukleozydy pirymidynowe
- Pirymidyn
- Ciąży
- Ciężarne
- Steroidy
- Związki sterownika
- Sterydy, fluorowane
- Pochodne benzenu
- Techniki diagnostyczne, chirurgiczne
- Kwasy sulfonowe
- Kwasy siarkowe
- Nukleozydy
- Pterins
- Perydyny
- Ciąży
- Amidohydrolazy
- Vinca alkaloidy
- Sesologanina alkaloidy tryptaminy
- Alkaloidy indole
- Indolizicyny
- Indolizyny
- Arabinonukleozydy
- Aminopterina
- Radioterapia
- Ciążone
- Pusta
- 11-hydroksykortykosteroidy
- Hydroksykortykosteroidy
- Hormony kory nadnerczy
- 17-hydroksykortykosteroidy
- Techniki diagnostyczne, neurologiczne
- Benzenezulfoniany
- Arylosulfoniany
- Kwasy arylosulfonowe
- Radioterapia, wspomagana komputerowo
- Związki sulfhydrylowe
- Niwolumab
- Deksametazon
- Metotreksat
- Cytarabina
- Winkrystyna
- Hydrokortyzon
- Asparaginaza
- Merkaptopuryna
- Dobesylan wapnia
- Biopsja
- Prowadzenie okazów
- Blinatumomab
- Kłucie kręgosłupa
- 21-fosforan deksametazonu
- N, N-dicykloheksylo-izoborneol-10-sulfonamid
- Calaspargaza Pegol
- azathiopuryna
- Merphos
- Pegaspargaza
- Radioterapia, zgodna
- Auricularum
- octan deksametazonu
- asparaginaza Erwinia chryzanthemi rekombinowana
- Hemisuksynian hydrokortyzonu
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- NCI-2020-06813
- U10CA180886 (Grant/umowa NIH USA)
- NCI-2020-06813 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- AALL1821 (Inny identyfikator: CTEP)
- AALL1821 (Inny identyfikator: Children's Oncology Group)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .